Paramount Diagnostics Lab picks Abluva for real-time data security

Paramount Diagnostics Lab has selected Abluva’s Data Runtime Security platform to protect patient data across its clinical operations in New Jersey. The move is aimed at strengthening real-time governance for sensitive health information as healthcare workflows increasingly use AI-assisted tools. Why it matters: - Paramount Diagnostics Lab operates in a highly regulated healthcare setting where patient health information must be protected in real time. - The deal is designed to add enforcement at the data layer, where information is actually accessed, instead of relying only on perimeter controls. - The selection also reflects growing pressure on healthcare providers to govern AI-assisted workflows without exposing sensitive data. What happened: - Paramount Diagnostics Lab selected Abluva’s Data Runtime Security platform to protect patient data across its clinical operations. - The agreement was announced on June 16, 2026. - Paramount is based in Edison, New Jersey. - Abluva is headquartered in Palo Alto, California. The details: - Abluva’s platform will enforce policy directly at the data source layer, where queries execute and data is accessed. - Every query from human users, applications and AI agents will be evaluated inline before data is returned. - The deployment does not require changes to existing data sources or applications. - The platform sits in front of existing data stores with no schema changes, no new users and no modifications to current systems. - Paramount plans to use the platform to govern what AI-assisted tools can access and where data can flow. - The company also plans to explore Abluva’s patent-pending self-adapting policies. - Those planned policies could automatically revoke write access at defined clinical milestones, such as a trial database lock, without manual intervention. - Abluva says the platform is built for real-time enforcement at the point of data access across humans, AI agents and non-human identities. - Abluva has filed 6 USPTO patent applications. - Abluva holds ISO 27001 and CSA Star Level 1 certifications. - The company serves customers across healthcare, manufacturing, retail and telecommunications in three countries. - A company representative said Paramount wanted protection at the data layer without disrupting how teams and systems already work. - Abluva’s co-founder and CEO said the partnership matters because Paramount was looking for real protection at the data layer rather than a checkbox solution. Between the lines: - Healthcare security vendors are increasingly being judged on whether they can control access at the moment data is used, not just when it enters the network. - AI adoption is raising the stakes because more tools and agents can touch patient data across more workflows. - The emphasis on inline governance suggests Paramount wants tighter control without adding operational friction. What’s next: - Paramount will roll out Abluva’s platform across its clinical operations. - Paramount is expected to test how the system handles AI-assisted workflows and policy enforcement at connected tool boundaries. - Paramount may also evaluate event-driven access controls tied to clinical milestones. - Abluva and Paramount included forward-looking statements about expected security, compliance and AI governance outcomes. The bottom line: - Paramount is betting that real-time, data-layer enforcement can improve patient-data protection without disrupting daily clinical work.